Form 8-K - Current report:
SEC Accession No. 0001193125-25-278392
Filing Date
2025-11-13
Accepted
2025-11-12 20:55:33
Documents
16
Period of Report
2025-11-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d28785d8k.htm   iXBRL 8-K 32231
2 EX-1.1 d28785dex11.htm EX-1.1 271766
3 EX-4.1 d28785dex41.htm EX-4.1 74867
4 EX-5.1 d28785dex51.htm EX-5.1 18311
8 GRAPHIC g28785g1112131230292.jpg GRAPHIC 1977
  Complete submission text file 0001193125-25-278392.txt   618338

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eldn-20251112.xsd EX-101.SCH 2846
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eldn-20251112_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eldn-20251112_pre.xml EX-101.PRE 11258
19 EXTRACTED XBRL INSTANCE DOCUMENT d28785d8k_htm.xml XML 3669
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 251475081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)